Boston Scientific May Now Have The Strongest Pipeline In Company History

Canaccord Genuity said in a Tuesday note Boston Scientific Corporation (NYSE: BSX) enjoys the most robust pipeline in its long, storied history. The firm also said the company is set to further augment the proportion of sales derived from faster-growth markets, many of which sport tailwinds.

The firm initiated coverage of Boston Scientific with a Buy rating and a Street-high price target of $36 for the shares.

Analyst Jason Mills said the company is primed to deliver top- and bottom-line growth above its peer group over the next few years, given its compelling portfolio of differentiated products.

The products include Watchman, LAAC, S-ICD, Synergy DES and Lotus/Acurate TAVR, while the company also offers several differentiated technologies in its dominant Med-Surg business.

See also: This Healthcare ETF Continues Beating Higher

The analyst thinks the stock will outperform large-cap med-tech peers over the next three years through three drivers, which fundamentally comprise his bullish thesis.

The firm said the company would spend about 90 percent of the $6.6 billion in free cash flow it estimates for the 2018-2020 timeframe, on M&A or returning cash to shareholders compared to 17 percent in the 2015-2017 timeframe.

Latest Ratings for BSX

Oct 2017	Canaccord Genuity	Initiates Coverage On		Buy
May 2017	Goldman Sachs	Initiates Coverage On		Neutral
Oct 2016	Citigroup	Maintains		Buy

View More Analyst Ratings for BSX
View the Latest Analyst Ratings

See more from Benzinga

• Veeco's Core Business Faces A 'Triple Threat,' Market Slowdown In 2018

• Next Year Will Be Weak For Kimberly Clark; Analyst Says Buy The Stock Anyway

• Why Western Digital Is Likely To Deliver A Q1 Beat And Raise

© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.